Constructing CSCs‐targeted CAR‐T cells overexpressing IL‐12, IL‐18, IL‐7, IL‐15 and IL‐21 cytokines to provide cytokine support in the immunosuppressive tumour microenvironment(TME)78Neutralization of immunosuppressive mediators within the TME, such as TGF‐β, IL‐10 and arginase I92The combination with checkpoint inhibitors: PD‐1/PD‐L1 or CTLA‐4 blocking antibodies96, 97. The gene discussed is CTLA4; the disease is neoplasm.